![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Grants Prelim Approval to Novartis, Astellas Drugs, but Not Janssen Drug
NICE Grants Prelim Approval to Novartis, Astellas Drugs, but Not Janssen Drug
December 17, 2015
The UK’s health cost-benefit watchdog has given provisional approval in draft guidances for Novartis’ novel heart failure drug Entresto, and recommended Astellas’ enzalutamide as a treatment for prostate cancer.
Meanwhile, NICE withheld recommending Janssen’s prostate cancer drug Zytiga (abiraterone acetate), saying the drug is a well-tolerated treatment that delays chemotherapy, but that it was not convinced the “uncertain evidence” for the long-term treatment benefit justified the cost, which was “significantly above what it would normally consider acceptable.”
Upcoming Events
-
21Oct